Podcasts about zepbound

So… Serena Williams shares she used GLP-1s to support her weight loss and the internet implodes with hot takes, shade, and side-eyes. Here's the truth: when it comes to midlife weight loss, some folks don't come to this decision lightly, and others are judging from the sidelines. If you've ever felt like you had to hide what's working for you because someone else might label it "cheating," this Fit Girl Magic podcast episode is your permission slip to shut that noise down. In this candid, smart, and hilarious conversation, I sat down with Dr. Megan Garcia Webb, triple board-certified in internal medicine and obesity medicine (yes, triple), to break down:   ·      What GLP-1s like Ozempic, Wegovy, and Zepbound actually do ·      Why “food noise” might be what's really driving your cravings ·      The real deal on side effects like muscle loss, gut issues, and does it really cause cancer ·      Who's a great candidate for these meds, and who should pause before jumping in ·      Why natural GLP boosters are more boring than sexy (but still matter) ·      How social media makes women feel like they're doing it “wrong”, no matter what they choose ·      The #1 most underrated weight loss tool (spoiler: it's not a supplement) ·      Whether you're GLP-curious, already on it, or side-eyeing it from afar, this episode is about giving you clarity, facts, and a whole lot of freedom. DM me or tag us if something in this conversation made you say, “Wait… I never thought of it like that!” Links + Resources: Dr. Megan Garcia Webb's website: YouTube channel: Previous Ozempic podcast Everything You Need to Know About Ozempic with Dr. Janese Lester    Facebook group Free Resources: https://www.fitgirlmagic.com/freeresources_podcast Website:  http://www.kimbarnesjefferson.com  FREE Challenge 5 Days To Break The All Or Nothing Instagram https://www.instagram.com/kimjeffersoncoach

I'm leaving for my yearly Disney trip for the T1D conference, and y'all — nothing will humble you more than a three-way dressing-room mirror. I tried on one of those athletic dresses and BAM: back-fat in the mirror I'd never noticed before. Cue the body image vacation panic. But I refused to let bad lighting and spandex steal my trip. In this episode, I tell the whole embarrassing story, exactly how I knocked myself out of that spiral, and why you absolutely cannot put your life on hold until the scale says so.

To read more of Derek's reporting on GLP-1 drugs, you can subscribe to his Substack here. GLP-1 drugs like Ozempic and Zepbound don't just help with Type 2 diabetes and weight loss. They seem to curb alcohol, cocaine, and tobacco use among addicts. In some studies, they prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease. They're associated with a lower risk of several cancers, including pancreatic cancer and multiple myeloma. Arthritic patients on the drugs experienced relief from knee pain that was “on par with opioid drugs.” A small study found that they reduce migraine headaches by 50 percent. And emerging research suggests they might even slow the rate of memory loss among people diagnosed with Alzheimer's. Is all of this real? And if it's real, how is one drug doing so many different things? And if it is doing all those things, why shouldn't we be developing versions of the drug for just about everyone? Today we have two guests: David D'Alessio, chief of endocrinology and metabolism at the Duke University School of Medicine; and Randy Seeley, a professor of surgery, internal medicine, and nutritional sciences at the University of Michigan. We talk about how these drugs work—why they seem to do everything—and how our understanding of them could make them better, more effective, more broadly useful. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: David D'Alessio and Randy Seeley Producer: Devon Baroldi Disclosure: Dr. Seeley has received research support from several pharmaceutical companies, including Eli Lilly, Diasome, and Amgen. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Welcome back to Ozempic Weightloss Unlocked, the show that brings listeners the most current news, research, and perspectives on Ozempic, the medication that has transformed weight loss conversations everywhere.Ozempic, generically known as semaglutide, was originally approved for type two diabetes by the FDA in 2017. Its follow-up, Wegovy, hit the market in 2021 explicitly for chronic weight management. Both drugs belong to a class called glucagon-like peptide-one receptor agonists. These medications work by mimicking a naturally occurring hormone that helps the body regulate blood sugar after meals while also reducing appetite by slowing the digestive process. Many patients taking Ozempic weekly have seen impressive reductions in body weight—up to 16 percent, according to data highlighted by the American Journal of Managed Care.The popularity of Ozempic exploded when its weight loss effects were amplified on social media and through celebrity endorsements. Demand surged, and global interest grew as more people sought medical solutions outside of diet and exercise alone. But Ozempic is not just hype—it's backed by multiple clinical trials and growing medical consensus, though not without debate.Researchers continue to push the boundaries, and major updates are underway. According to Fox News Digital and the Times of India, scientists at Tufts University have developed a next-generation experimental drug aimed at delivering weight loss of up to thirty percent—nearly matching surgical outcomes but without the operation. This new compound works across four hormone pathways: GLP-1, GIP, glucagon, and peptide YY, aiming to deliver robust weight loss with fewer side effects like nausea and muscle loss. The “quadruple-action” drug is still in early preclinical stages, tested only in cells—not yet in humans or animals—but represents a bold step towards more personalized, gentle, and sustainable weight management therapies.For now, single-hormone agents like Ozempic remain widely prescribed. Experts urge those on GLP-1 medications to partner closely with their clinicians, focusing on daily protein, hydration, and resistance training to mitigate risks such as muscle loss and malnutrition. Nutritional support is key, as well as regular follow-ups.Alongside medical progress, litigation and warnings continue to surface. The Lawsuit Information Center reports that thousands of claimants have entered into multidistrict litigation over Ozempic and similar drugs, citing side effects like gastroparesis, or stomach paralysis, and rare forms of vision loss including neovascular age-related macular degeneration and optic neuropathy. A 2025 study out of the University of Toronto found semaglutide users twice as likely to develop macular degeneration compared to others—a small risk, but real and statistically significant. Another concern comes from JAMA Otolaryngology–Head & Neck Surgery, showing a possible increased risk of thyroid cancer among GLP-1 agonist users. The defense argues that many of these side effects are rare, and some findings may be linked to increased medical surveillance, rather than the drug itself. Physicians and patients are encouraged to weigh these risks alongside the benefits and always discuss options thoroughly before starting treatment.As for what comes next, listeners should keep an eye on innovations underway: oral drugs like orforglipron, combination therapies such as CagriSema, and monthly injectables from major firms—all targeting more effective weight loss with easier dosing and fewer downsides. Tirzepatide, branded as Zepbound, is currently considered one of the most potent with trial data showing up to twenty-one percent body weight loss.The obesity epidemic is far from solved, but the next wave of treatments could make weight loss less about suffering and more about smart science. Whether listeners are considering Ozempic, awaiting newer options, or just tuning in for updates, the biggest takeaway is this: work with a trusted healthcare provider, stay informed about the latest findings, and balance medication with healthy lifestyle habits.Thank you for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe and share. This has been a Quiet Please production—for more, check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

En la edición de hoy del Radar Empresarial, abordamos la reciente decisión de Novo Nordisk de reducir significativamente su plantilla. La farmacéutica danesa eliminará alrededor de 9.000 puestos de trabajo a nivel global, de los cuales 5.000 corresponden a Dinamarca. Este recorte representa aproximadamente el 11,5% de su fuerza laboral total. Además, la compañía ha vuelto a revisar a la baja sus expectativas para 2025. Según explicó el nuevo director ejecutivo, Mike Doustdar, la empresa debe adaptarse a un mercado cambiante, especialmente el segmento de la obesidad, que se ha vuelto mucho más competitivo y centrado en el consumidor. La realidad para Novo Nordisk es complicada. La feroz competencia en el mercado de medicamentos para tratar la obesidad ha afectado negativamente su valoración bursátil. De liderar el sector, la empresa ha sido superada por SAP y se enfrenta a la amenaza constante de ASML Holding. Sus acciones han perdido cerca de un 45% de su valor desde el año pasado, tras años de fuerte crecimiento gracias al éxito de productos como Ozempic y Wegovy, lanzados hace cinco años. La rivalidad con empresas como Eli Lilly y otras farmacéuticas emergentes que ofrecen alternativas más económicas ha deteriorado su posición. En este contexto, el nuevo CEO Mike Doustdar asumió el mando el pasado 30 de julio, sucediendo a Lars Fruergaard Jørgensen. Doustdar comenzó su gestión con medidas audaces, como ofrecer Ozempic por 499 dólares mensuales para pagos en efectivo. La compañía también está desarrollando píldoras para bajar de peso, aunque su aprobación por la FDA podría demorar hasta diez meses. Mientras tanto, medicamentos como Plenity o Contrave se ofrecen por unos 250 dólares, frente a otros más caros como Wegovy o Zepbound, que superan los 1.000 dólares. Novo Nordisk no solo enfrenta presión comercial, sino también legal. Ha iniciado 132 demandas por patentes en EE. UU., ganando la mayoría. Recientemente, acusó a Hims & Hers de infringir su propiedad intelectual y promover productos riesgosos. Asimismo, rompió su colaboración con esta empresa por distribuir versiones ilegítimas. A esto se suma la amenaza arancelaria por parte de Donald Trump. ¿Podrá la farmacéutica dar un giro a esta desafiante coyuntura?

If you've been hearing all the buzz about GLP-1 medications like Ozempic, Wegovy, or Zepbound, and you're wondering if they could be the right fit for you at midlife, this is the episode to press play on. We brought on nurse practitioner and health optimization expert Amy Wrenn to demystify what GLP-1s actually are, how they work, who they're for, and what you really need to know about taking them during perimenopause and menopause. Amy is passionate, informed, and totally relatable—she cuts through the hype to bring clarity to a topic that's been wrapped in confusion and judgment.In this conversation, we get real about our own experiences, bust some myths, talk side effects (yep, we go there), and explore the broader context of hormone therapy, weight gain, metabolic dysfunction, and the importance of doing what works for your individual body and life. Whether you're curious, cautious, or already on a GLP-1, this is a must-listen packed with valuable insights.  Episode Highlights:[0:00] - Welcoming Amy Wrenn and kicking off our deep dive into GLP-1s [3:10] - What exactly are GLP-1s, and how do they work in your body? [5:00] - Understanding insulin resistance, perimenopause, and why midlife changes everything [6:57] - Real-life examples of "metabolic mayhem" that hits out of nowhere [8:03] - Challenging the lazy stereotype: GLP-1s are not a quick fix [10:08] - The far-reaching benefits: inflammation, PCOS, cognitive health, and more [12:10] - Social media hype vs. safe medical prescribing—know the difference [13:46] - Compounded medications vs. name-brand prescriptions: what to watch for [17:33] - Who qualifies for GLP-1s, and what do providers look for? [20:43] - It's not about skinny—it's about healthy: the real goal of treatment [22:34] - Common side effects: what to expect and how to manage them [25:25] - Nutrition matters: prioritizing protein, avoiding high-fat traps [26:38] - Surprising benefits: reduced alcohol cravings, better food boundaries [28:12] - Coming off GLP-1s: what it looks like, and when it's okay to stay on [31:48] - Does your body adapt over time? Amy explains habituation and dosing [33:32] - The power trio: GLP-1s, HRT, and resistance training [36:08] - Hormone therapy explained: symptom relief vs. long-term prevention [40:51] - Why we're not getting this info from our doctors—and how to change that [42:24] - Where to follow Amy and keep learning more  Links & ResourcesFollow Amy Wrenn, NP on Instagram: https://www.instagram.com/np_wrenn If today's discussion resonated with you or sparked curiosity, please rate, follow, and share "Insights from the Couch" with others. Your support helps us reach more people and continue providing valuable insights. Here's to finding our purposes and living a life full of meaning and joy. Stay tuned for more!Come hang out with us in The Chat, our free community for midlife women, where we keep theconversation going at insightsfromthecouch.org/the-chat. And don't forget todownload our free guide 7 Skills to Master Midlife so you can stop living small, start taking action, andlive the life you really want at insightsfromthecouch.org/midlife-roadmap.

I'm back from my summer break, and today we're talking about what it really means to come out of survival mode and step into a new season of life. When you're just trying to make it through, the world feels blurry. You don't even notice the little things piling up around you. But once you start to shift, it's like everything comes back into focus: the appointments you've been putting off, the house that suddenly needs cleaning, and most importantly, you.In this episode, I'm sharing a summer recap (including an upcoming Disney trip I didn't think would happen), how back-to-school season has me reflecting on my own routines, and why fall is the perfect reminder that change can be beautiful.

In this episode of the Game Changing Health podcast, host Gianna speaks with nurse practitioner Chace Franks, an expert in GLP-1 medications. Chase is a nurse practitioner at IVIM Health which is a telehealth company that recently published exciting new data with semaglutide efficacy rivaling tirzepatide with the IVIM model of care involved in treatment. They discuss the evolution of GLP-1s, their effectiveness in weight management, and the role of telehealth in providing accessible healthcare. Chace shares insights from his experience in prescribing GLP-1s, the importance of supportive healthcare providers, and the challenges of insurance coverage. The conversation also touches on the impact of social media in educating patients and the personal experiences of both speakers with GLP-1s. They emphasize the need for patients to advocate for themselves and seek providers who listen to their concerns.  Follow Chase on TikTok: https://www.tiktok.com/@bourbonrx?_t=ZT-8zeFAlyoBEk&_r=1Follow Chace on Instagram: https://www.instagram.com/bourbonrx1?igsh=MWdrZ3g3N2VzZXU1NQ==Check out IVIM here: https://ivimhealth.sjv.io/QjdoYAKeywords:GLP-1, obesity management, telehealth, weight loss, healthcare providers, insurance coverage, patient education, social media, chronic conditions, health investment ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wonder why the same weight loss plan can work wonders for one person but barely move the needle for another?Or why some people respond really well to medications like Wegovy, while others struggle with side effects or see minimal results? That's exactly what precision obesity medicine aims to answer—and today, we're diving into it with one of the world's leading experts.We're joined by Dr. Andres Acosta, a true pioneer in obesity medicine and the creator of the obesity phenotypes concept. He's board-certified in internal medicine, gastroenterology, hepatology, obesity medicine, and nutrition. At the Mayo Clinic, he co-directs the Nutrition and Obesity Research Program and leads the Precision Medicine for Obesity program, focusing on matching the right treatment to the right patient with fewer side effects.Dr. Acosta's research is supported by the National Institutes of Health, with more than 145 peer-reviewed papers in top journals. His work has been featured in The New York Times, TIME, CNN, and NPR, and he's earned “40 Under 40” recognition and co-founded Genomic Sciences—just a glimpse of his many accomplishments.If you've ever felt frustrated by trial-and-error weight loss or wondered if there's a more scientific way to find what actually works for you, you're going to want to hear what Dr. Acosta shares in this episode.Connect with Dr. Acosta:Mayo Clinic: mayu.eduPhenomix Sciences: WebsiteConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

#162 The Injection Craze + AI Psychosis Welcome to The Third Hour, your go-to space for Conscious Culture, Conscious Radar, and insights that nourish your curiosity and expand your perspective.This Week:

When Serena Williams—the most dominant tennis player and cultural trailblazer—reveals her use of a weight loss drug and becomes the face of a sleek new ad campaign, the internet doesn't just react…it explodes. But what's really fueling the debate around celebrities, body image, and the next wave of GLP-1 weight loss meds like Zepbound? On this episode of “Better Than Fine,” host Darlene Marshall delivers her hot take on Serena's headline-grabbing weight loss journey, unpacking the science, the social firestorm, and the deeply personal questions these choices raise for public figures and their followers. Why do we care when someone like Serena goes public—but barely shrug when Charles Barkley does the same? Are influencers betraying the body positivity movement, or just owning their choices? And what's really at stake for your mental and physical health if you're considering these trending prescriptions? From the celebrity endorsement backlash to the shady side of hidden weight loss, and from cultural shifts in body ideals to the overlooked risks—like muscle loss—Darlene breaks it all down with expert insight. Whether you're a wellness pro, a GLP-1 skeptic, or just curious about the real impact of these "miracle drugs," this conversation will change how you think about health, honesty, and the bodies we celebrate. If you like what you just consumed, leave us a 5-star review, and share this episode with a friend to help grow our NASM health and wellness community! The content shared in this podcast is solely for educational and entertainment purposes. It is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek out the guidance of your healthcare provider or other qualified professional. Any opinions expressed by guests and hosts are their own and do not necessarily reflect the views of NASM. Introducing NASM One, the membership for trainers and coaches. For just $35/mo., get unlimited access to over 300 courses, 50% off additional certifications and specializations, EDGE Trainer Pro all-in-one coaching app to grow your business, unlimited exam attempts and select waived fees. Stay on top of your game and ahead of the curve as a fitness professional with NASM One. Click here to learn more. https://bit.ly/4ddsgrm

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Ženy XYZ #9: Tenisová šampionka Serena Williams zeštíhlela s pomocí léku napodobujícího funkci hormonu GLP-1, který reguluje chuť k jídlu a pocit sytosti. Světu to dala slavná sportovkyně vědět v reklamní kampani firmy, v níž jako člen správní rady a investor působí její manžel a která k existujícím léčivům jiných výrobců dodala další s názvem Zepbound. Znamená to, že tenistka, která celou kariéru bořila rasové i genderové stereotypy, nakonec podlehla tlaku na uniformní štíhlost, která se znovu vrací do módy, a vzala to medicínskou “zkratkou”? Nebo naopak ukázala, jak obtížné je snížit hmotnost, i když je člověk vrcholový sportovec a má k tomu odpovídající podmínky? A že tedy hrají roli i jiné faktory než pevná vůle spojená s jídelníčkem a pohybem? A mají léky založené na imitaci GLP-1 nějaké rizika? V devátém díle feministického podcastu Ženy XYZ o tom debatují redaktorky Respektu Markéta Plíhalová, Clara Zanga a Silvie Lauder. 

Visit All Our Links https://linktr.ee/manonthemounjaro GLP-1 Heart Study https://onthepen.substack.com/p/new-study-glp-1-drugs-protect-the

In today's episode we want to start by addressing the response creator Chloe Baradinsky (Chloe Barry Hang) had to our latest episode where we discussed broadly the recent influx of content creators in Afghanistan, following her posting her recent travels there.ABC Podcast ABC article NBC article We then discuss the tens of thousands who attended ‘March for Australia' rallies on Sunday, they were violent, led by nazis and met by counterprotestors in most cities. Everyone's close and dearest friends, Taylor Swift and Travis Kelce, have announced their engagement! The Prime Minister announced the end of diplomatic relations with Iran last week, proving they can take action to cut ties with some countries. Sabrina Carpenter has released her seventh studio album, Mans Best Friend, directly addressing album cover controversy. 23 time grand slam champion Serena Williams has candidly spoken about her GLP-1 weight loss, dropping more than 14 kilos with Zepbound, which is part of the same family as the better-known name of Ozempic.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered what it would be like to live without the constant mental chatter about food?For many, those thoughts never seem to stop. From planning the next meal to feeling guilt after eating, food can take up an overwhelming amount of mental space. It's exhausting, and for some, it feels impossible to break free.This ongoing noise, now widely known as food noise, is more than just hunger or cravings—it's the mental weight of always thinking about food, and it can affect every part of daily life. In this episode, we're diving deep into the mental weight of food noise, why it happens, and how dieting history often fuels this constant chatter. We also talk about where the term “food noise” came from, how it's reshaping conversations around weight and eating, and what the latest research is teaching us about the biology behind it.But we don't stop there. We also share practical ways of taking action against food noise—from mindset shifts to medical support—and explain why GLP-1 medications are helping so many people finally quiet the noise, giving them the mental space and freedom they've been missing.If you've ever felt stuck in that cycle, this episode is for you. Listen to the full episode to get the complete discussion and actionable insights.Article link: https://www.nature.com/articles/s41387-025-00382-xConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Visit our links: https://linktr.ee/manonthemounjaro

Wow!  Most people know about GLP1 drugs like Ozempic and Zepbound.  These drugs cause rapid and profound weight loss - in the face...and also in the genitals.  Women are reporting deflated labia majora mons pubis after losing so much weight.  On this episode, we talk about how I am re-inflating labia and mons pubis with hyaluronic acid filler.  And yes, I'm doing this along with a board certified gynecologist.  Tune in to learn about Ozempic vulva!  We also discuss cleaning up the skin after a summer of punishment.  

Welcome back to Ozempic Weightloss Unlocked, the source for the latest news and research about Ozempic and its impact on weight loss, health, and modern living. Today, we are diving into what is happening right now in the world of Ozempic, from how it works to the lifestyle changes it brings and the newest headlines surrounding this medication.Ozempic was originally developed as a treatment for type two diabetes but quickly gained widespread attention when studies showed it could help people lose an average of ten to fifteen percent of their body weight over six to twelve months. According to clinical trials and real-world testimonies, people using Ozempic are experiencing steady, sustainable weight loss, often seeing a reduction of one to three pounds per week when the medication is combined with healthy eating and regular activity.The science behind Ozempic involves its active ingredient, semaglutide, which mimics a gut hormone called glucagon-like peptide-1. This hormone helps regulate blood sugar, slow digestion, reduce appetite, and make you feel fuller after meals. The result: people naturally eat less without feeling deprived. According to Harvard School of Public Health, the success of Ozempic is not just about the medicine itself but also depends on diet and exercise. Experts emphasize that to make the most of the benefits, Ozempic users should focus on balanced eating, enough protein, regular movement, and strength training, which help preserve muscle mass and maintain long-term results.For those wondering about side effects, gastrointestinal symptoms like nausea or constipation are the most common, especially in the first few weeks. These often improve over time but are a reminder that proper nutrition and hydration are essential. Some people also report loss of muscle if protein intake and exercise are neglected, so working closely with your healthcare provider to monitor your health and adapt your plan is key.Ozempic is often compared to Wegovy. Both contain the same active ingredient, semaglutide, but while Ozempic is typically prescribed for diabetes and used off-label for weight loss, Wegovy is FDA-approved specifically for obesity and weight management. There is a broader landscape too, with medications like Zepbound, also known as tirzepatide, delivering even larger average weight loss in some studies—up to twenty percent or more of total body weight. As new options arrive, the market for weight loss solutions is changing rapidly, giving patients and doctors more choices than ever.Perhaps most interestingly, the benefits of Ozempic reach beyond just weight or diabetes. Cutting-edge research reported by Henry Ford Health suggests that medications like Ozempic may help curb addictive behaviors, including cravings for alcohol or other substances. While the research is in early stages, the idea that a medication for diabetes and obesity could help treat addiction is an unexpected but promising development we'll be following closely.A frequent question is what happens after stopping Ozempic. Research published in the journal Diabetes, Obesity and Metabolism shows that people often regain up to two-thirds of the weight they lost when the medication is discontinued, and benefits to blood sugar, cholesterol, and inflammation also tend to fade. This rebound effect is why ongoing lifestyle habits—like healthy eating and consistent movement—remain crucial for lasting results.Finally, inspiring personal stories continue to emerge. From people losing fifty pounds in just six months, to testimonies of reduced cravings, better energy, improved sleep, and renewed confidence, the lifestyle changes go far beyond the scale.As always, Ozempic is not magic. Its power comes when combined with strong support, healthy habits, and medical supervision. But as 2025 unfolds, Ozempic and other GLP-1 medications are opening doors for millions of people seeking safer, more effective ways to achieve lasting health.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, please subscribe, share, and stay with us for even more updates and real-life stories.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

If you've ever felt frustrated because your weight loss feels too slow, this episode is for you. Dr. Lisa talks about why so many people quit on themselves when the scale doesn't move fast enough, and why that's often a mistake. You'll hear about Kathy, a client who lost 70 pounds over four years, and why her “snail's pace” transformation may be the smartest way to succeed.Dr. Lisa shares her Top 5 predictors of long-term weight loss success, including why patience matters more than perfection, how showing up consistently changes everything, and why you need to stop giving away your power to the scale.Whether you're using lifestyle changes, medications like Wegovy or Zepbound, or a mix of both, this episode will help you reset your expectations, stay motivated, and finally build the kind of lasting results that stick. Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Today we're revisiting our conversation with one of the greatest athletes of all time, Serena Williams, who just made news with Vogue by opening up about using GLP-1 Zepbound after her pregnancy. Almost three years ago, she made news again when she announced she's taking a step back from tennis in the September issue of Vogue. In our first-ever episode of The Run-Through, Serena shared what life looks like post-tennis; everything from being a mom, a VC with Serena Ventures and a children's book author. The Run-Through with Vogue is your go-to podcast where fashion meets culture. Hosted by Chioma Nnadi, Head of British Vogue; Chloe Malle, Editor of Vogue.com; and Nicole Phelps, Director of Vogue Runway, each episode features the latest fashion news and exclusive designer and celebrity interviews. Learn about your ad choices: dovetail.prx.org/ad-choices

Ozempic has dominated headlines again this week as Novo Nordisk announced a major price cut, making the diabetes drug available for 499 dollars per month to eligible cash-paying patients in the United States for the first time through their NovoCare pharmacy program and in partnership with telehealth provider GoodRx. This move follows similar pricing for Wegovy, a sister drug prescribed primarily for weight loss, and responds to mounting public and political pressure to reduce drug costs in the US, which have traditionally far outpaced those in other countries. The rapid expansion of access has sparked renewed debate on the cultural and medical impact of GLP-1 drugs, with product demand and public interest remaining extremely high.In the same news cycle, Oprah Winfrey once again became a focal point of national conversation about weight loss and Ozempic. Recent photos posted from her vacation in Italy, where she was seen truffle hunting, have drawn widespread notice for her noticeably slimmer figure. While the food adventure was part of the public narrative, much of the commentary was focused on Oprah's dramatic transformation. Earlier this year on her podcast, Oprah spoke candidly about her experience with so-called GLP-1 medications. She shared that after starting on the medicine, which functions by suppressing appetite, she began to understand how differently people can experience hunger. For years, she admits, she attributed thinness to willpower, assuming that some people simply had better self-control around food. The drug shifted her perspective, making her realize the powerful biological factors at play and how GLP-1 drugs can create a level playing field for those with obesity, a condition the talk show icon now insists is a disease of the brain, not a failure of character.Oprah's public acknowledgment of using weight loss medication was itself notable, given the intense stigma and the climate of secrecy around pharmaceutical weight loss among celebrities. She described feeling "relief," "redemption," and gratitude that she could finally manage chronic weight struggles with a tool that's medically approved. Despite having initially resisted the idea, citing a belief that using drugs was the “easy way out,” Oprah has since changed her position and has called for an end to self-blame and societal shaming. In her words, shame has been replaced by a sense of liberation, both from her own self-judgment and from external criticism. She no longer sees the use of weight loss drugs as something to be hidden or ridiculed.Medical experts weighing in this week have reiterated that Ozempic and other GLP-1 medicines do produce significant weight loss and improvements in cholesterol and triglyceride levels as long as patients continue taking them. Ziyad Al-Aly, chief of research at the Veterans Affairs St. Louis Healthcare System, emphasizes that the drugs enhance not just weight management but overall metabolic health. However, there are crucial caveats: studies published this week in Diabetes Obesity and Metabolism confirm that stopping GLP-1 medication typically results in regaining as much as two-thirds of the lost weight and a reversal of most health benefits. This so-called rebound effect has caused concern among physicians, who urge patients to understand the drugs are best considered a long-term therapy rather than a short-term fix.As demand spikes, news of rare but concerning adverse effects, such as potential vision changes, has kept the safety discussion alive, though current expert consensus is that for most people prescribed these medications appropriately, the benefits outweigh the risks. Meanwhile, Novo Nordisk and other drug makers continue racing to expand access through direct pharmacy programs, with Eli Lilly also announcing price reductions and new supply chain solutions for its own competing drug Zepbound.On social media and in mainstream culture, public acceptance of GLP-1 treatments appears to be moving quickly, especially with high-profile advocates like Winfrey openly discussing their use and encouraging an end to the blame game around obesity. As Oprah underscored in her latest episodes, the real shift is away from stigma and toward a greater understanding of the science of obesity and the power of new medications to address it as a medical condition, not a moral failing.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

It's nearly impossible to turn on the television or open a magazine without seeing advertisements for the latest weight loss trend: GLP-1 medications, commonly known as Ozempic, Mounjaro, Wegovy, and Zepbound. Approximately 15 million people are estimated to have tried these drugs for weight loss. However, as with any emerging health trend, it's important to consider whether these medications are safe and cost-effective.What are the risks and benefits of these drugs? Is the pharmaceutical industry providing a quick fix for the approximately 42% (or 100 million) U.S. citizens who are obese? Are these medications the only solution to the obesity epidemic, or are lifestyle and dietary changes essential for long-term success? Dr. Nicole Dorotik joins us in this episode to address these questions and more as we explore the latest trends in the pursuit of health and wellness.Special Guest: Dr. Nicole Dorotik Dr. Nicole Dorotik earned her medical degree from the University of Arizona College of Medicine and completed her residency at Long Beach Memorial Hospital in Long Beach, California. She is board-certified in Family Medicine and has over 20 years of clinical experience. Along with her professional accomplishments, Nicole is the proud mom to three great kiddos. Show notes:Weight Comes Back When You Stop Taking Drugs Like Ozempic, Study Finds.https://www.sciencealert.com/weight-comes-back-when-you-stop-taking-drugs-like-ozempic-study-finds#A new era of weight loss: Mental health effects of GLP-1 drugs.https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-healthRx History: The Rise of GLP-1s.https://www.innovativerxstrategies.com/rx-history-glp1s/Unintended consequences: Weight loss drugs are changing the way consumers buy groceries.https://www.post-gazette.com/business/healthcare-business/2025/08/17/glp1-ozempic-grocery-store-food-price-weightloss/stories/202508070069.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Today is a Plus SideZ Rewind! Two years ago, we sat down with the one and only Rosie O'Donnell at the dawn of our movement for affordable access to GLP-1 medications & ending the stigma around treating obesity as a disease. Now, as we stand well into season five with thousands of new subscribers, so it's time for a little time-travel! We're bringing you a “Rewind” of that pivotal conversation to let our new listeners hear where it all began and let our longtime supporters see just how far we've come.In this flashback, we revisit that summer of 2023 when the Mounjaro $25 Savings Card Coupon was ending and people were flocking to compound GLP-1 which still had a lot of question marks surrounding it. And the shortage of all GLP-1s was growing. There was no Zepbound or cash pay price or branded vials. It was $1400-1000 a month go get access to branded GLP-1s. With more voices in the conversation today, we're measuring our progress from that. Oh how far we've come! We can now get branded GLP-1 for under $500. That's a ton of movement in a short time. But let's get it lower! Keep the faith. Let's get loud AND change things! ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Think sleep apnea is just about loud snoring? Think again. This common condition is a serious health issue that affects a staggering number of people with both type 1 and type 2 diabetes. In this eye-opening episode, Dr. Steve Edelman is joined by Dr. Jeremy Pettus, who shares his own recent and unexpected diagnosis of obstructive sleep apnea. From recognizing the subtle symptoms to navigating the diagnosis process and starting treatment, Dr. Pettus offers a firsthand account of what it's like to confront this underdiagnosed condition. This episode is a crucial wake-up call, revealing how untreated sleep apnea can impact everything from your heart health and blood pressure to your energy levels and insulin resistance. Whether you or a loved one has diabetes, this is essential listening.Key Topics:What is Sleep Apnea? An explanation of how the airway collapses during sleep, leading to a drop in oxygen levels and triggering a "fight-or-flight" response throughout the night.Symptoms to Watch For: A breakdown of the classic signs, including loud snoring and gasping for air, as well as less obvious daytime symptoms like excessive fatigue, morning headaches, and low libido.Who Is at Risk?: A look at the surprisingly high prevalence of sleep apnea, especially among people with diabetes, affecting up to 80% of those with type 2 and half of those with type 1.Key Risk Factors: A guide to the factors that increase your chances of developing sleep apnea, such as weight, neck size, age, gender, and lifestyle habits like alcohol consumption.Getting Tested: An overview of the diagnostic process, from the simple STOP-BANG screening questionnaire to the modern convenience of home sleep tests.Effective Treatment Options: A comprehensive look at treatments that can improve your health, including lifestyle changes, CPAP therapy, and the new FDA-approved use of weight-loss medications like Zepbound for sleep apnea. ★ Support this podcast ★

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

People are losing their minds over Cracker Barrel, Eli Zaret joins us as the Detroit Tigers are on fire, Kirk Herbstreit cries again, Magnum P.I.G., Lil Naz X nuts, Jizzlaine Maxwell's DOJ interview, and Diamond David Lee Roth is always the showman. Kirk Herbstreit is a bumbling mess discussing Lee Coso retiring. Eli Zaret drops by to discuss Magnum P.I. Day at Comerica Park, the surging Detroit Tigers, Pitcher Drew Sommers debut, the Detroit Lions Super Bowl odds, Jason Benetti's many hats, the Lions 53-man roster, Shilo Sanders BLOWN OUT, CFB is back, more sports dildos and more. Warning: Fox 2 Stephanie Mead thirst trap. Cracker Barrel changed their logo and people are melting down. Steak ‘n Shake is on the attack. Michael Strahan gave the CEO time to do a commercial on Good Morning America. Marc loves the McDonaldland Meal… if the employee knows what it is. Halsey defends her movie Americana, which bombed at the box office. Lil Nas X has lost his mind and his clothes. SNL is ready to make some changes. Donald Trump's hands look old… cause he's old. Morgan Wallen is boycotting The Grammy's but won't say why. Jay-Z is really loaded. He the richest musician in history. Male cheerleaders are now getting backlash despite being around for quite a while. David Lee Roth is sounding awful lately. Like REALLY bad. Hold me closer, Tony Danza! Serena Williams is getting crap for taking the fat shot… and doing a commercial for Zepbound. Hey Amanda Bynes… why you look different? These brothers totally got it on. Travel with Livii has some pretty incredible travel requests. Jizzlaine Maxwell spills. Prince Andrew, Bill Clinton and Donald Trump are cleared of wrongdoing… yeah right. Donald Trump gets a victory over Letitia James. She'll appeal it. John Bolton was raided on Friday. Britney Spears remains crazy. Jenelle Evans claims to have made over $1.5M on OnlyFans. She's at odds with her son, Jace. Lil Tay calls out every woman over 25 who is not rich. Jeff Bezos wants his wife to be the next Bond Girl. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

Welcome to Ozempic Weightloss Unlocked, the podcast where we bring you the latest news and honest insights about Ozempic, its medical uses, and how it's shaping lives and health choices today.Right now, Ozempic, whose active ingredient is semaglutide, is grabbing headlines for two main reasons. First, its original role as a once-weekly injectable for controlling blood sugar in type 2 diabetes. And second, its growing off-label use for weight management, even in people without diabetes. According to recent studies, those using Ozempic for type 2 diabetes typically experience around six to seven percent body weight reduction. Meanwhile, newer research reveals that people seeking weight loss alone — even those without diabetes — can see average losses up to fifteen percent of their starting body weight over about 68 weeks. That data comes from high-profile clinical trials and is supported by publications like Drugs.com and Indiana University blogs.The main way Ozempic works is by mimicking a gut hormone to boost insulin and slow digestion, which curbs appetite and helps regulate blood sugar. Many people using Ozempic report feeling fuller after smaller meals and noticing dramatically reduced cravings, especially for snacks and sweets. Patients often say the weight loss feels different compared to past diets, as it's less about constant hunger battles and more about natural appetite control.What about safety? Like any medication, Ozempic has trade-offs. The most common side effects are mild to moderate stomach issues—think nausea, diarrhea, or constipation, especially as your body adjusts to the drug. There's also an increase in reports of “Ozempic face,” a phrase describing loose skin and more prominent wrinkles, although experts clarify this is from rapid weight loss rather than the drug itself. Some people experience hair thinning and muscle loss, again tied to losing weight quickly. According to guidance from the University of Kentucky and Kentucky Health News, these risks are present with most major weight loss methods, not just with Ozempic.Rare but serious side effects have surfaced and deserve attention. Investigations and lawsuits in 2025 have highlighted complications like gastroparesis — that's a severely delayed emptying of the stomach — and a condition called non-arteritic anterior ischemic optic neuropathy, which affects vision. There's also a small risk of gallstones, gallbladder issues, pancreatitis, dehydration-related kidney problems, and concerns about thyroid C-cell tumors, though that last risk is still being studied mostly in animals.Ozempic is not the only medication in the spotlight. Wegovy, also containing semaglutide but at higher doses, is approved specifically for chronic weight management and typically results in even more robust weight loss, often around fifteen percent. Meanwhile, new drugs like tirzepatide, marketed as Zepbound or Mounjaro, are now showing even greater effect sizes. According to New England Journal of Medicine coverage summarized by the University of Kentucky, tirzepatide can lead to an average of twenty percent or more body weight lost in some patients, far outpacing Ozempic and making headlines as possibly the most effective approved injection to date.With all this buzz, it's crucial for listeners to have honest conversations with their health providers. Ozempic and newer medications are changing expectations around weight loss, but they also bring a new set of considerations. Not every listener will respond the same way, and long-term effects are still being studied.That wraps up this episode of Ozempic Weightloss Unlocked. Thank you for tuning in and letting us help illuminate the facts behind the headlines. Do not forget to subscribe to stay updated on the most important developments. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

See omnystudio.com/listener for privacy information.

If injectable weight loss drugs like Zepbound can help people lose 20% of their weight, what about a once-a-day pill that achieves 12% weight loss, without the needles and sky-high cost? In this episode, Lisa Oldson, MD shares Andrea's journey through the maze of weight loss medications and introduces the promising new drug orforglipron. You'll hear how this oral GLP-1 agonist compares to popular injectables, why it could be a game-changer for millions, and the top five reasons to consider medication as part of a comprehensive weight loss plan. Whether you're curious about new treatments, concerned about side effects, or looking for affordable options, this episode breaks down what you need to know about orforglipron and the future of weight loss medicine.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter by emailing us at Team@SmartWeightLossCoaching.com, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Wellness is more than weight, and health is more than numbers. In this episode of BHT Bytes, host Sharlee Dixon is joined by Peter Fenger to unpack the complex intersections of diet culture, body image, and mental health. From the rise of weight-loss fads in the '80s and '90s to the emergence of body positivity and fat visibility movements, we trace how cultural messages about size and health have shaped generations. The conversation dives into the psychological toll of diet culture—covering disordered eating, negative self-image, and the mental health struggles tied to societal ideals. We also explore the new wave of GLP-1 weight-loss drugs like Ozempic, Wegovy, and Zepbound—hailed by some as groundbreaking, but raising critical questions about identity, stigma, and long-term impact. Together, Sharlee and Peter break down the science, the stigma, and the shifting narratives of weight and wellness in today's world.   Follow Behavioral Health Today on Instagram at: https://www.instagram.com/behavioralhealthtoday/ Follow us on TikTok at: https://www.tiktok.com/@behavioralhealthtoday Follow us on Threads at: https://www.threads.net/@behavioralhealthtoday Or watch us live on YouTube at: https://www.youtube.com/channel/UCvOeCMGsF7B2gNBHuWxt-fQ

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Join us as we chat with Dr. Spencer Nadolsky, founder of Sequence (now part of Weight Watchers), about the real-world journey of living with GLP-1 medications like Wegovy and Ozempic. We dive into the stages of this journey—why weight regain can happen, how to navigate plateaus, and how to rethink exercise and food tracking without the guilt. Dr. Spencer breaks down why obesity is truly a chronic condition and offers down-to-earth advice on managing each phase. It's all about understanding the path, avoiding common pitfalls, and feeling empowered on your GLP-1 journey_______________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Today, we're diving into one of the most talked-about topics in health and weight loss right now: GLP-1 medications like semaglutide and the newer dual GIP/GLP-1s like tirzepatide. You've probably seen the headlines, scrolled past a few TikToks, or heard a friend mention it — but with all that noise comes a lot of confusion, half-truths, and flat-out myths. Today we're breaking it all down. What's real? What's hype? And what do you actually need to know if you're using these medications — or thinking about it? Let's separate science from scare tactics and get to the truth, one myth at a time. Myth #1: GLP-1s Cause Dangerous Muscle Loss The claim:  “GLP-1s cause massive muscle loss.” Truth: This is an overstatement. Some loss of lean mass is normal with any kind of weight loss — whether it's through diet, medication, or surgery. What studies show is that with medications like semaglutide (Wegovy) and tirzepatide (Zepbound), about 20–25% of the total weight lost comes from lean mass, and the rest is fat — which is exactly what we're targeting in obesity treatment. That 20–25% figure isn't unique to these meds; it's actually pretty typical in weight loss without focused resistance training or optimized protein intake. You may also hear “You'll lose all your muscle and become frail on GLP-1s.” Truth: You won't “lose all your muscle.” In fact, muscle loss is preventable by maintaining adequate protein intake, resistance training, and managing weight loss pace. Furthermore, many patients gain strength and mobility as excess weight comes off. And lastly, my favorite myth is “You can't preserve muscle on GLP-1s.” Truth: That's completely false — muscle loss isn't inevitable on GLP-1s if you take the right approach. You can absolutely preserve muscle by making a few intentional choices: aim for enough protein each day (a good goal is around 0.8 grams per pound of body weight), include some strength or resistance training a couple times a week, and avoid losing weight too quickly. These simple steps go a long way in protecting your lean mass while still getting all the benefits of weight loss. One study on semaglutide showed that people lost an average of about 15% of their body weight, and only around 3–4% of that was lean mass. So if someone drops 30 pounds, maybe 6 to 8 of those pounds might be lean mass—not ideal, but definitely not disastrous either, and very manageable with the right lifestyle habits.  The truth is, while some lean mass loss is expected with any type of weight loss, research shows that most of the weight lost on GLP-1s is actually fat, not muscle. For example, in the STEP 1 trial, about 80% of the weight lost on semaglutide came from fat, and only about 20% from lean tissue (as we mentioned earlier).  The SURMOUNT-1 trial with tirzepatide showed similar results—significant fat loss with relatively preserved muscle, especially when paired with resistance training. And that's important, because preserving muscle during weight loss helps protect metabolism, strength, and overall health. With good nutrition and movement, GLP-1s can lead to healthier body composition—not just a lower number on the scale. Okay, moving along to the next myth … Myth #2: GLP-1s Can Cause Blindness The truth: This myth stems from concerns about diabetic retinopathy worsening, which is tied to how quickly blood sugar drops, not to the drug itself. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), a small subset of patients with pre-existing advanced diabetic retinopathy saw transient worsening—but only in those with rapid improvements in A1c. No increased rates of blindness or new-onset retinopathy have been found in non-diabetic patients using GLP-1s for weight loss. The bottom line is that those without advanced diabetic eye disease, there's no increased risk of blindness. Patients with diabetic retinopathy should be monitored closely—but this is about glycemic management, not a direct effect of the medication. Myth #3: GLP-1s Cause Kidney or Liver Damage The truth: This is false. In fact, GLP-1 agonists may protect kidney and liver function—especially in patients with diabetes or fatty liver disease. The most recent notable study showing kidney‑protective effects of a GLP‑1 receptor agonist is the FLOW trial, which evaluated semaglutide in people with type 2 diabetes and chronic kidney disease (CKD). This double‑blind, randomized, placebo‑controlled trial included 3,533 participants followed for a median of 3.4 years and found that semaglutide reduced the risk of major kidney‑related events—including kidney failure, substantial eGFR decline, and death from renal or cardiovascular causes—by 24% compared to placebo. A 2025 meta-analysis of multiple randomized controlled trials (11 studies, 85,373 participants) concluded that GLP‑1 receptor agonists reduced the risk of composite kidney failure outcomes by 18%, kidney failure by 16%, and all‑cause death by 12%. And let's not forget the SMART trial, involving obese patients with kidney disease but without diabetes, found that semaglutide protected kidney function in this non‑diabetic, CKD‑affected population.  When it comes to the liver, there's actually growing evidence they're actually helping reverse non-alcoholic fatty liver disease (NAFLD). The STEP 1 MRI substudy and SURPASS-3 MRI substudy have shown people on these medications can reduce liver fat by 30 to even 50% and in some cases, completely resolve liver inflammation — that more serious form called NASH, where fat is combined with inflammation and early scarring. The LEAN trial found that nearly 60% of people taking semaglutide had resolution of NASH, without worsening their liver scarring. That's huge. And even better, we're seeing these effects even in people who don't have diabetes. Just losing weight helps fatty liver, but these meds seem to do more than that — they actually target inflammation and fat storage in the liver itself.. The bottom line is GLP-1s are not nephrotoxic or hepatotoxic. In fact, they may be organ-protective—especially for people with underlying metabolic issues. Myth #4: These Drugs Lead to Bone Loss The claim: “You'll get osteoporosis from losing too much weight!” The truth: While extreme weight loss can affect bone density, GLP-1s themselves do not cause bone loss, and may even have neutral or protective effects on bone. A 2022 study in Bone found no significant change in BMD (bone mineral density) in adults treated with semaglutide for obesity. While the SUSTAIN and PIONEER programs found no increased risk of fractures in semaglutide-treated patients versus placebo. Truly, concerns about bone loss are more relevant in extreme calorie restriction or eating disorders—not evidence-based GLP-1 treatment with appropriate nutrition. Myth #5: Everyone Gets Gastroparesis The claim: “These medications paralyze your stomach” The truth: GLP-1s slow gastric emptying, which is part of how they work—making you feel full longer. But this is dose-dependent and typically reversible. A 2023 FDA safety review found that true gastroparesis is extremely rare and resolves when the drug is stopped. Reality check: Nausea, early satiety, and mild bloating are common but manageable side effects. True, lasting gastroparesis is not typical, especially when doses are titrated gradually. Myth #6: GLP-1s Make Your Hair Fall Out The claim: “You'll lose a ton of hair—just like with crash diets” The truth: Hair shedding is not directly caused by GLP-1 medications. Instead, it's often a temporary, non-scarring condition called telogen effluvium, which can happen with any rapid weight loss, regardless of the method. A 2023 analysis from the American Academy of Dermatology emphasized that telogen effluvium is common with surgical or medical weight loss, especially if patients lose more than 10% of their body weight within a few months. In clinical trials like STEP and SURMOUNT, hair loss was not listed as a common side effect, but patient-reported data show it occurs occasionally—likely tied to nutritional stress, not the drug itself. So why does hair loss happen? We've talked about this before, but I don't want to leave this important information out.  Hair follicles are sensitive to internal stress. Rapid changes in caloric intake, nutrient levels (like iron, zinc, and biotin), or hormone balance can push hairs into the shedding phase. This is a delayed effect, often showing up 2–3 months after weight loss begins, and it typically resolves within 6–12 months. What helps is slower, sustained weight loss, prioritizing protein intake, supplementing iron, zinc, and biotin if deficient, and avoiding very low-calorie diets and over-restriction. Myth #6: GLP-1s Cause Dehydration It's a common myth that GLP-1 medications cause dehydration — but that's not exactly true. The medication itself doesn't directly dehydrate you. What can happen is that some people experience nausea, vomiting, or a reduced appetite early on, which can lead to drinking less water without realizing it. That's where the dehydration risk comes in. A good general rule for staying hydrated is to aim for half your body weight in ounces of water per day. So, for example, if you weigh 160 pounds, try to drink around 80 ounces daily — more if you're active or live in a hot climate. Electrolytes can also be really helpful, especially if you're feeling tired, dizzy, or crampy. I like LMNT packets — they're a clean option with no sugar and a good balance of sodium, magnesium, and potassium. The sodium in LMNT packets helps keep you hydrated by pulling water into your cells and helping your body retain the fluids it needs to function properly. Just one a day can make a big difference in how you feel. Myth #7: You Have to Stay on GLP-1s Forever or You'll Gain All the Weight Back The claim: “As soon as you stop taking it, all the weight comes back” The truth: Yes—some weight regain is likely after stopping GLP-1 medications. But that doesn't mean they're ineffective or that you're doomed to rebound completely. The same pattern happens after any type of weight loss intervention, whether it's a diet, surgery, or medication. The STEP 4 trial (Wilding et al., 2022) showed that participants who stopped semaglutide after 20 weeks regained an average of 6% of their weight loss over the next year. But it's important to note that they still weighed less than at baseline—and many continued to experience improvements in blood pressure, cholesterol, and insulin sensitivity. Similarly, in SURMOUNT-4, patients who stopped tirzepatide also regained weight, but less than they lost. So why does this weight gain happen? I feel like the answer to this is obvious, but I've found that it's not.  GLP-1s change your appetite and hunger cues. Once the medication is stopped, your body's baseline hunger signals return—and often with increased intensity, due to metabolic adaptation. But this isn't unique to GLP-1s. The same thing happens after crash diets, keto, intermittent fasting, or bariatric surgery if long-term changes aren't made. The real issue isn't the drug—it's the lack of a plan after the drug. To help make results sustainable, we need to use the medication as a tool, not a crutch. We should use it to help us lose weight and understand our hunger cues, while transitioning to a whole foods, protein based diet coupled with resistance training to help preserve and build muscle.  Just remember, if you're coming off a GLP-1 and want to keep the momentum going, the key is to approach it thoughtfully. Tapering slowly under medical supervision can help your body adjust and reduce the chances of weight regain. At the same time, this is a great moment to double down on the habits that helped you feel your best while on the medication. Think ongoing support—like working with a health coach, joining a support group, or even doing behavioral therapy—to help reinforce those long-term lifestyle changes. It's not just about what you stop; it's about what you keep doing that matters most. You don't necessarily have to stay on GLP-1s forever—but if you stop without a plan, some weight regain is very likely. Think of them like glasses: they help you see clearly while you build the habits to eventually navigate without them. For some, that may mean staying on a lower maintenance dose long-term—just like with blood pressure or cholesterol meds. What are my final thoughts? I want to be clear—GLP-1s aren't magic. But they are powerful tools when paired with education, support, and smart lifestyle changes.  Myths like ‘you'll go blind,' ‘you'll lose all your hair,' or ‘you'll be stuck on these meds forever' aren't just misleading and downright false—they discourage people from getting real help.  So if you're thinking about these medications, get informed, ask the hard questions, and make your decision based on science—not fear. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sarepta has released new safety data for their gene therapy Elevidys, showing zero ambulatory deaths in patients with Duchenne muscular dystrophy. This data confirms the therapy's positive risk/benefit profile. Meanwhile, Novo Nordisk's rapid rise and fall was driven by GLP-1s like Ozempic and Wegovy, leading to a plummet in stock value. Insmed has received FDA approval for the first bronchiectasis drug and DPP1 blocker, Brinsupri. Texas has accused Eli Lilly of "bribing" prescribers to push their drugs Mounjaro and Zepbound, leading to a new lawsuit. Genscript is entering a new era of innovation and trust, offering exclusive promos and events. Additionally, Tang Capital is on a buyout binge in the biotech industry, while a top ARPA-H official has departed in protest of cuts to mRNA funding. The biotech industry continues to see contractions with companies like AbSci, Fate, and Oric downsizing. In career advice, loyalty is seen as a flawed strategy that can cost individuals opportunities.Arrowhead, a biotech company, has emerged as a savior in the RNA interference (RNAi) pipeline after Sarepta faced troubles unrelated to Arrowhead's assets. Concentra Biosciences, a biotech shell company, has been on a buying spree, acquiring four biotechs in the past month and seven so far this year. President Trump's most favored nation drug pricing policy is seen as unfavorable for all parties involved. Novo Nordisk experienced a rapid rise and fall due to the success of ozempic and wegovy. Lilly is facing drug pricing pressure while defending its injectable GLP-1 empire. Novartis is rumored to be considering acquiring RNA specialist Avidity. Despite safety concerns, Sarepta beat Q2 estimates, but not due to sales of its product Elevidys. Various biotech companies are downsizing while others are receiving significant investments.

In this episode, Mike discusses the latest GLP-1 craze, which has to do with healthy weight individuals using these medications. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Na jaren van van een gebrek aan beursgangen, gaat het over een paar weken gebeuren. Na de zomer komen er bedrijven naar de beurs. Dat verwachten ze bij Goldman Sachs. Alle groenen staan op sein in Europa, zeggen ze tegen het FD. Wij kijken deze aflevering wat dat voor jou als belegger betekent. Wat voor bedrijven komen er dan naar de Amsterdamse beurs bijvoorbeeld? En zijn dat ook aandelen die je moet hebben?Hebben we het ook over een mogelijke beursgang van webbrowser Chrome. Geen idee of dat gaat gebeuren, maar wél dat er ineens enorme interesse in het onderdeel van Google is. Een startup biedt 35 miljard dollar. Een ander (naar verluidt) 50 miljard. Wanneer gaat Google overstag?Over afscheid nemen gesproken: het was bekend dat president Trump af wil van Fed-baas Jerome Powell. Maar nu blijkt ook dat er een heel elftal aan mogelijke vervangers is. We bespreken de namen en wat je er van kan verwachten.Ook kan je verwachten dat dit in de uitzending zit: De Japanse beurs tikt een record aan, net als Amerikaanse indices. Is dat terecht? Trump wil dat Goldman Sachs z'n hoofdeconoom ontslaat Shell lijdt een pijnlijke nederlaag En China krijgt gelijk. Er zitten trackers in Amerikaanse chips... See omnystudio.com/listener for privacy information.

Every year at Haymarket Media, we bring in a cohort of about 30 interns for eight weeks over the summer to learn the ropes across our business media, medical communications and internal operations units.For us here at MM+M, our intern exit interview gets recorded and sent out into the world. Over the past few weeks on the podcast, you've heard from our summer intern, Lola Offenback.In addition to contributing to our discussions of the top news stories in the Trends segment, she has led insightful conversations with the team at Breakthrough T1D as well as Derrick Gastineau from Currax Pharmaceuticals.You've also seen her reporting appear on our website where she has penned articles about Eli Lilly's latest Zepbound campaign, Supreme Group's acquisition of  rare disease agency Pivot Design and how Opella shined at Cannes this year.Though Lola's time with us comes to an end this Friday, she's our feature interview for today's episode – sharing her experiences at MM+M, what she's learned over the last few weeks as well as how she'll carry those lessons forward as she heads back to class and then into her post-college career.For our Trends segment, we're talking about the good, the bad and the ugly of pharma's Q2 earnings season.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.- The recent changes in obesity medication coverage have raised concerns among providers and patients.- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.- Advocacy efforts are crucial in reversing negative trends in medication coverage.- Patients often face challenges with prior authorization processes when switching medications.- The cost of obesity medications is a significant barrier to access for many patients.- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.- The conversation emphasizes the importance of patient-centered care in obesity treatment.- There is a call for making obesity medications more affordable and accessible to patients.https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationClick to join Dr. Spencer's online clinic if you need help with this 

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why getting obesity medications like Wegovy or Zepbound feels sooo complicated and honestly, kinda impossible sometimes?Between high costs, confusing insurance rules, and endless paperwork, even patients who qualify often struggle to actually start treatment.To help us break it all down, I'm joined by Dr. Nikita Shah, a board-certified obesity medicine physician and founder of WeightSense in Orlando, Florida. She focuses on practical, health-first weight care and also serves on the Medical Society of Central Florida board and the Obesity Pillars Journal editorial board. She's all about helping patients find real-world solutions that actually work.In this episode, we cover everything you need to know about accessing obesity medications, including:Why obesity is a real medical condition, not a personal failure.How cost and insurance create the biggest hurdles.The different coverage rules for medications like Wegovy, Zepbound, and Ozempic.What prior authorization really involves—and how to get through it.Affordable medication options like Qsymia and Contrave.Why most compounded anti-obesity medications aren't the safest choice.If you're ready to finally understand the process, cut through the confusion, and learn the smartest steps to get started, listen to the full episode now!Connect with Dr. Shah:Instagram: nikitashahdoWebsite: Weight SenseBlog Mentioned: Understanding Insurance CoverageConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

When it comes to weight loss, the scale isn't the only thing that changes—your reflection and self-image often transform too. In this episode, I talk about a topic gaining attention in the media and social circles: "Ozempic face" and the emotional and physical effects of rapid weight loss, especially for those using GLP-1 medications like Wegovy, Zepbound, or Ozempic. I share a story about a friend who hesitated to increase her dosage due to concerns about skin changes, which opened the door to a larger discussion on body image during weight loss. I explain that these facial and skin changes—such as sagging, wrinkles, or looking more tired—aren't exclusive to medication use but are common with any significant weight loss, especially as we age.  Furthermore, I walk through ways to manage these concerns, like slowing down weight loss, prioritizing resistance training and protein, staying hydrated, considering aesthetic treatments, and most importantly, shifting focus from appearance to overall health. I emphasize the importance of support, tuning out unsolicited comments, and curating a healthier social media feed.  If you're navigating weight loss and struggling with body image changes like "Ozempic face," listen to this empowering episode for real talk, expert tips, and compassionate support on your journey.   Episode Highlights: What “Ozempic face” really means and why it happens Emotional impact of rapid weight loss and changing appearance How to manage body image concerns during weight loss Practical tips: strength training, hydration, and pacing weight loss Cosmetic treatment options and when to consider them The role of social media in shaping unrealistic expectations Reframing the focus from appearance to overall health and wellness Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro

In this episode, we dive deep into the biggest stories shaping the markets right now. Intel has officially fallen out of the top 10 semiconductor companies — is it too late for them to catch up, and which 3 chipmakers should investors focus on instead? We also break down how stock options can be used as a powerful wealth-building tool when used the right way.With Nvidia flirting with a $4 trillion valuation after an explosive 870% AI-led rally, we discuss whether it's headed for a meltdown or another breakout — and which overlooked metric might signal what's next. Bitcoin also hit a new all-time high heading into Crypto Week, and we break down what this means for the broader crypto market.Next, we analyze who the real winners and losers in Big Tech have been since Trump took office, and what it means for investors moving forward. With U.S. equity fund inflows collapsing from $31.6 billion to just $2.1 billion, we ask: are you buying the dip or parking cash on the sidelines? Lastly, we look at Eli Lilly and whether its new Zepbound pill could drive a potential 40% surge in the stock over the next year.EYLU 24 Hour 50% off Sale (Code: Marketmondays) https://eyluniversity.comInvest Fest Ticket Link: https://investfest.com#Investing #StockMarket #Crypto #Bitcoin #Nvidia #Intel #EliLilly #Zepbound #TechStocks #InvestFest #EarnYourLeisure #MarketMondays #FinancialFreedom #OptionsTradingOur Sponsors:* Check out PNC Bank: https://www.pnc.comSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy